Supernus Pharmaceuticals has been granted a patent for a compound of Formula I, including stereoisomers and salts, for treating central nervous system disorders. The compound includes various groups like substituted alkane, heterocyclic, or pyridine, making it versatile for pharmaceutical compositions. GlobalData’s report on Supernus Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Supernus Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Supernus Pharmaceuticals's grant share as of February 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent (Publication Number: US11919889B2) discloses a compound of Formula II, stereoisomer thereof, and/or a salt thereof, along with various derivatives and compositions. The compound, when L is CH2 or a substituted pyridinecarboxylic acid group like dimethyl pyridine-dicarboxylate, shows potential for treating central nervous system disorders. The patent also covers methods for making the compound, involving specific reactive compounds like methylene dibromide, 3,5-pyridinedicarboxylic acid, and methyliminodiacetic acid.
Furthermore, the patent includes a composition comprising the disclosed compound and a pharmaceutically acceptable excipient, aimed at providing a method for treating central nervous system disorders. The method involves administering the composition to a subject, showcasing the potential therapeutic applications of the compound. The detailed methods for making the compound, utilizing specific compounds of formulae, highlight the intricate process involved in synthesizing the disclosed compound for potential pharmaceutical use. The patent's focus on central nervous system disorders and the specific compounds and compositions involved provide a glimpse into potential advancements in the field of neuropharmacology.
To know more about GlobalData’s detailed insights on Supernus Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
